London / New York 18 May 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), (the “Company” or “Tiziana”), a biotechnology company focused on innovative therapeutics for oncology,
Tiziana Life Sciences Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
Prospectus Publication Announcement
OKYO Pharma Announces Positive Data and Results in an Animal Model using Topically Administered OK-201 to Treat Neuropathic Ocular Pain
Tiziana Life Sciences to participate in a Fireside Chat on 28 April 2021 at 10:30 a.m. EDT
NEW YORK and LONDON, April 13, 2021 – Tiziana Life Sciences plc (NASDAQ: TLSA; LSE: TILS), today announced that its former subsidiary, Accustem Sciences Limited (“Accustem”), intends to file a
Tiziana Plans Phase 2 Clinical Study in Moderate to Severe Covid-19 Patients with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
OKYO announces the appointment of Dr Rajkumar Patil as Chief Scientific Officer
Gabriele Cerrone, Chairman of Tiziana Life Sciences, to give an interview on Bloomberg Television US at 1:20 PM ET Today
Tiziana Life Sciences Interview to Air on Bloomberg Television US on the RedChip Money Report
OKYO Pharma has U.S. Patent Issued Covering its Lipid Conjugated Peptide Analogues for treating Ocular Pain and Inflammation
